News And Media

Agennix is a private biotechnology company developing a first-in-class molecule with potent immunological activity for the treatment of cancer and wound healing. The Company’s lead molecule, talactoferrin, is an immunomodulatory protein with a novel mechanism of action. The Company is developing an oral liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers.

Agennix has completed two randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer (NSCLC) evaluating talactoferrin as monotherapy in patients who had failed one or two prior therapies for locally advanced or metastatic NSCLC and in combination with chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC. Both trials met their primary endpoints; improvement in overall survival for the monotherapy trial and improvement in response rate for the first-line trial. Agennix is currently preparing to initiate two Phase III trials in NSCLC, as monotherapy in patients who have failed two or more prior regimens and in first-line in combination with chemotherapy.